A Phase 2 Placebo-Controlled Double-Blind Multicenter Study to Evaluate the Efficacy Safety and Tolerability of DCR-PHXC Solution for Injection (subcutaneous use) in Patients with Primary Hyperoxaluria
Brief description of study
The purpose of this research is to test a new experimental drug for use in people with primary hyperoxaluria (PH). The study drug is called DCR PHXC, and it is given by subcutaneous injection. The purpose of this study is to learn more about how DCR PHXC works in the body, and how well it helps the liver make less oxalate to reduce symptoms of PH in patients at least 6 years of age with primary hyperoxaluria type 1 (PH1) or primary hyperoxaluria type 2 (PH2).
Clinical Study Identifier: s18-02015
ClinicalTrials.gov Identifier: NCT03847909
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
